Clinical Trial

Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 1, 2025 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
This phase 1 study in China will evaluate the safety and immunogenicity of the Recombinant Zoster Vaccine, LYB004 in adults aged 40 years and older.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-07; most recent amendment 2025-03-26.
Status change: Not Yet Recruiting → Recruiting 2025-03-20
Trial Details
NCT Number NCT06874842
Lead Sponsor Guangzhou Patronus Biotech Co., Ltd.
Conditions Herpes Zoster (HZ)
Enrollment 92 participants
Start Date 2025-03-13
Primary Completion 2026-02 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2025-04-01